Yeah, I would think Aspire would rather buy low if and when they buy more, as that depends on sp and results.
I found the below link a while back while checking out Aspire. It describes a financing agreement Aspire provided to Viking Therapeutics. Aspire paid $1.50/sh in August of 2016, the sp was as low as 88 cents in July of 2017, trading now at $10.52 as I type, traded as high as 13.43 this past June. No reverse splits although I should note they are on the Nazdaq and are covered by 8 analysts.
Far as I can tell they completed a phase 2 in March 2018 and scheduled another ph2 in December 2018